Exclusive: UPMC launches another biotech, rooted in the tumor microenvironment
In Mani Mohindru’s telling, Novasenta is “as biotech-y as you can get.”
The CEO of the latest startup out of UPMC’s sprawling research apparatus says her biotech is looking for novel targets to make new cancer therapies, as compared to the proliferation of biotechs popping up with programs going against targets that are already validated or in the public domain.
The company has secured $40 million in Series A funds led by the Pittsburgh institution, based on 10 years of work out of the Hillman Cancer Center’s Tumor Microenvironment Center. Three programs have been propelled to center stage, with one or two of them slated for IND-enabling studies later next year with the aim of clinical trials kicking off in 2024, Mohindru told Endpoints News.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.